Lots of Interest in Molecular Dx from Investors, Vendors as JP Morgan Conference Wraps Up | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
SAN FRANCISCOAs the 25th annual JP Morgan Healthcare Conference came to a close last Thursday in San Francisco, it was clear that investors and molecular biology tool vendors agree that the molecular diagnostics market is a major opportunity that should not be shunned.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.